# The Opioid Crisis: Resources

## Overview

This document provides a curated bibliography of the most important resources for understanding the opioid crisis, including academic research, government reports, books, data sources, and organizations. Resources are organized by category and annotated with descriptions of their relevance.

---

## Foundational Academic Research

### Addiction Science and Treatment

- Mattick, Richard P., et al. "Buprenorphine Maintenance versus Placebo or Methadone Maintenance for Opioid Dependence." *Cochrane Database of Systematic Reviews* (2014). -- The definitive systematic review of MAT effectiveness, demonstrating superior outcomes for buprenorphine and methadone compared to placebo
- National Academies of Sciences, Engineering, and Medicine. *Medications for Opioid Use Disorder Save Lives*. Washington, DC: National Academies Press, 2019. -- Comprehensive evidence review concluding that MAT reduces mortality by approximately 50% and should be available to all patients with OUD
- Volkow, Nora D., and A. Thomas McLellan. "Opioid Abuse in Chronic Pain--Misconceptions and Mitigation Strategies." *New England Journal of Medicine* 374, no. 13 (2016): 1253-1263. -- Influential review by NIDA Director on the neuroscience of opioid addiction and evidence-based treatment
- Wakeman, Sarah E., et al. "Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder." *JAMA Network Open* 3, no. 2 (2020): e1920622. -- Large study demonstrating that MAT is associated with significantly lower overdose risk compared to non-medication treatments

### Epidemiology and Surveillance

- Hedegaard, Holly, Arialdi M. Minino, and Margaret Warner. "Drug Overdose Deaths in the United States, 1999-2020." *NCHS Data Brief*, No. 428. Hyattsville, MD: National Center for Health Statistics, 2021. -- Standard CDC statistical summary of overdose death trends
- Ciccarone, Daniel. "The Rise of Illicit Fentanyls, Stimulants and the Fourth Wave of the Opioid Overdose Crisis." *Current Opinion in Psychiatry* 34, no. 4 (2021): 344-350. -- Analysis of the emerging "fourth wave" involving polysubstance use
- Spencer, Merianne, et al. "Drug Overdose Deaths Involving Fentanyl, 2011-2016." *National Vital Statistics Reports* 68, no. 3 (2019). -- Detailed epidemiological analysis of the fentanyl wave

### Root Causes and Social Determinants

- Case, Anne, and Angus Deaton. *Deaths of Despair and the Future of Capitalism*. Princeton: Princeton University Press, 2020. -- Landmark analysis linking opioid deaths to broader patterns of economic decline, social disintegration, and "deaths of despair"
- Ruhm, Christopher J. "Deaths of Despair or Drug Problems?" *NBER Working Paper No. 24188* (2018). -- Critical analysis examining whether deaths are driven by economic despair, drug supply, or both
- Hollingsworth, Alex, Christopher J. Ruhm, and Kosali Simon. "Macroeconomic Conditions and Opioid Abuse." *Journal of Health Economics* 56 (2017): 222-233. -- Empirical analysis of the relationship between economic conditions and opioid misuse

### Harm Reduction

- Platt, Lucy, et al. "Needle Syringe Programmes and Opioid Substitution Therapy for Preventing Hepatitis C Transmission in People Who Inject Drugs." *Cochrane Database of Systematic Reviews* (2017). -- Systematic review of syringe services program effectiveness
- Walley, Alexander Y., et al. "Opioid Overdose Rates and Implementation of Overdose Education and Nasal Naloxone Distribution in Massachusetts." *BMJ* 346 (2013): f174. -- Key study demonstrating that community naloxone distribution reduces overdose mortality
- Marshall, Brandon D.L., et al. "Reduction in Overdose Mortality after the Opening of North America's First Medically Supervised Safer Injecting Facility: A Retrospective Population-Based Study." *The Lancet* 377, no. 9775 (2011): 1429-1437. -- Study of Vancouver's Insite SCS showing 35% reduction in overdose deaths in surrounding area

### Pharmaceutical Industry and Regulatory Failure

- Van Zee, Art. "The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy." *American Journal of Public Health* 99, no. 2 (2009): 221-227. -- Detailed analysis of Purdue Pharma's marketing strategy
- Hadland, Scott E., et al. "Association of Pharmaceutical Industry Marketing of Opioid Products with Mortality from Opioid-Related Overdoses." *JAMA Network Open* 2, no. 1 (2019): e186007. -- Study demonstrating that county-level opioid marketing was associated with subsequent overdose deaths
- U.S. Government Accountability Office. "OxyContin: FDA Oversight of its Promotion." GAO-03-1023T (2003). -- GAO investigation of FDA's failure to adequately oversee OxyContin promotion

---

## Government Reports and Data Sources

### Federal Agency Reports

- CDC. "Annual Surveillance Report of Drug-Related Risks and Outcomes." National Center for Injury Prevention and Control, updated annually. -- Comprehensive annual data on prescribing, overdose, and treatment trends. Available at: https://www.cdc.gov/drugoverdose/
- SAMHSA. "National Survey on Drug Use and Health (NSDUH)." Annual report. -- Primary source for national prevalence data on substance use and treatment access. Available at: https://www.samhsa.gov/data/nsduh
- SAMHSA. "National Survey of Substance Abuse Treatment Services (N-SSATS)." Annual report. -- Data on treatment facility capacity and services. Available at: https://www.samhsa.gov/data/nssats
- NIDA. "Overdose Death Rates." National Institute on Drug Abuse. -- Regularly updated overview of overdose mortality data and trends. Available at: https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates
- DEA. "National Drug Threat Assessment." Annual report. -- Assessment of drug trafficking threats including fentanyl supply chain analysis. Available at: https://www.dea.gov/documents
- ONDCP. "National Drug Control Strategy." Annual report. -- Presidential administration's drug policy framework and budget priorities. Available at: https://www.whitehouse.gov/ondcp/
- GAO. "Drug Misuse: Most States Have Good Samaritan Laws and Research Indicates They May Have Positive Effects." GAO-21-248. March 2021. -- Analysis of Good Samaritan law implementation and effectiveness
- CRS. "The Opioid Epidemic and Federal Efforts to Address It: Frequently Asked Questions." Congressional Research Service. Updated regularly. -- Comprehensive overview of federal response programs and legislation

### CDC Prescribing Guidelines

- Dowell, Deborah, et al. "CDC Clinical Practice Guideline for Prescribing Opioids for Pain--United States, 2022." *MMWR Recommendations and Reports* 71, no. 3 (2022): 1-95. -- Updated prescribing guideline replacing the 2016 version; emphasizes individualized care and flexible approaches
- Dowell, Deborah, Tamara M. Haegerich, and Roger Chou. "CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016." *MMWR Recommendations and Reports* 65, no. 1 (2016): 1-49. -- Original guideline that significantly influenced prescribing practices

### Data Portals

- **CDC WONDER**: https://wonder.cdc.gov/ -- Mortality data including drug overdose deaths by substance, demographics, and geography
- **CDC NCHS Provisional Drug Overdose Death Counts**: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm -- Most current (provisional) overdose death data
- **SAMHSA Behavioral Health Treatment Services Locator**: https://findtreatment.gov/ -- Treatment facility locator
- **DEA ARCOS (Automation of Reports and Consolidated Orders System)**: Retail drug distribution data (partially available through litigation releases)
- **PDAPS (Prescription Drug Abuse Policy System)**: https://pdaps.org/ -- State law tracking for prescription drug and opioid-related policies
- **ODMAP (Overdose Detection Mapping Application Program)**: https://odmap.org/ -- Near-real-time overdose spike detection system

---

## Books

### Investigative and Historical

- Macy, Beth. *Dopesick: Dealers, Doctors, and the Drug Company That Addicted America*. New York: Little, Brown and Company, 2018. -- Pulitzer finalist; comprehensive narrative of the crisis from Appalachian origins through the fentanyl wave
- Keefe, Patrick Radden. *Empire of Pain: The Secret History of the Sackler Dynasty*. New York: Doubleday, 2021. -- National Book Critics Circle Award winner; definitive account of the Sackler family's role in the opioid crisis
- Quinones, Sam. *Dreamland: The True Tale of America's Opiate Epidemic*. New York: Bloomsbury Press, 2015. -- National Book Critics Circle Award winner; traces the parallel rise of OxyContin marketing and Mexican heroin distribution
- McGreal, Chris. *American Overdose: The Opioid Tragedy in Three Acts*. New York: PublicAffairs, 2018. -- Journalist's account focusing on regulatory and corporate failures
- Meier, Barry. *Pain Killer: An Empire of Deceit and the Origin of America's Opioid Epidemic*. New York: Random House, 2018. (Updated edition) -- One of the earliest investigative books on Purdue Pharma and OxyContin

### Policy and Science

- Case, Anne, and Angus Deaton. *Deaths of Despair and the Future of Capitalism*. Princeton: Princeton University Press, 2020. -- Economic analysis of the structural conditions underlying the crisis
- Maia Szalavitz. *Undoing Drugs: The Untold Story of Harm Reduction and the Future of Everything*. New York: Hachette Go, 2021. -- History and advocacy for harm reduction approaches
- Hart, Carl. *Drug Use for Grown-Ups: Chasing Liberty in the Land of Fear*. New York: Penguin Press, 2021. -- Neuroscientist's argument for drug decriminalization and individual autonomy
- Humphreys, Keith. *Freedom from Addiction: Turning the Tide of Compulsive Drug and Alcohol Use through Policy Change*. Forthcoming. -- Addiction policy researcher's framework for evidence-based reform

### Memoir and Lived Experience

- Kiedis, Anthony. *Scar Tissue*. New York: Hyperion, 2004. -- Musician's memoir of heroin addiction
- Moyers, William Cope. *Broken: My Story of Addiction and Redemption*. New York: Viking, 2006. -- Journalist's account of addiction and recovery
- Helton, Ryan Hampton. *American Fix: Inside the Opioid Addiction Crisis--and How to End It*. New York: All Points Books, 2018. -- Recovery advocate's policy-focused account

---

## Key Organizations

### Federal Government

| Organization | Role | Website |
|-------------|------|---------|
| SAMHSA | Treatment funding, OTP regulation, prevention | https://www.samhsa.gov/ |
| NIDA | Addiction research | https://nida.nih.gov/ |
| CDC Injury Center | Surveillance, prevention, prescribing guidance | https://www.cdc.gov/injury/ |
| FDA CDER | Drug approval, safety, opioid REMS | https://www.fda.gov/drugs/ |
| DEA Diversion Control | Scheduling, quotas, enforcement | https://www.deadiversion.usdoj.gov/ |
| ONDCP | Policy coordination | https://www.whitehouse.gov/ondcp/ |
| CMS | Medicare/Medicaid coverage policy | https://www.cms.gov/ |

### Research and Policy

| Organization | Focus | Website |
|-------------|-------|---------|
| Johns Hopkins Bloomberg Opioid Research Center | Research, policy analysis | https://opioidprinciples.jhsph.edu/ |
| RAND Drug Policy Research Center | Evidence-based drug policy research | https://www.rand.org/well-being/justice-policy/centers/dprc.html |
| Pew Charitable Trusts Substance Use Prevention and Treatment Initiative | State policy research | https://www.pewtrusts.org/en/projects/substance-use-prevention-and-treatment-initiative |
| Brandeis University Opioid Policy Research Collaborative | Policy research and evaluation | https://www.brandeis.edu/opioid-policy/ |
| RTI International | Program evaluation, research | https://www.rti.org/ |

### Advocacy and Service

| Organization | Focus | Website |
|-------------|-------|---------|
| Shatterproof | Evidence-based treatment, quality measurement | https://www.shatterproof.org/ |
| National Harm Reduction Coalition | Harm reduction policy and practice | https://harmreduction.org/ |
| Faces and Voices of Recovery | Recovery advocacy | https://facesandvoicesofrecovery.org/ |
| Partnership to End Addiction | Family support, research | https://drugfree.org/ |
| NAMA Recovery | Medication-assisted treatment advocacy | https://www.namarecovery.org/ |
| Drug Policy Alliance | Drug policy reform | https://drugpolicy.org/ |

### Professional Organizations

| Organization | Focus | Website |
|-------------|-------|---------|
| American Society of Addiction Medicine (ASAM) | Clinical standards, workforce development | https://www.asam.org/ |
| American Academy of Addiction Psychiatry (AAAP) | Psychiatry-based addiction medicine | https://www.aaap.org/ |
| Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA) | Medical education | https://amersa.org/ |
| National Association of Drug Court Professionals (NADCP) | Drug court standards and training | https://www.nadcp.org/ |

---

## Legal Resources

### Key Court Cases

- *Harrington v. Purdue Pharma*, 603 U.S. ___ (2024) -- Supreme Court rejected initial Purdue bankruptcy plan granting Sackler family civil immunity; subsequent renegotiation increased Sackler payments
- *United States v. Safehouse*, 985 F.3d 225 (3d Cir. 2021) -- Third Circuit ruled that a proposed Philadelphia safe consumption site would violate federal law (21 U.S.C. 856)
- *Pesce v. Coppinger*, 355 F. Supp. 3d 35 (D. Mass. 2018) -- Federal court ruled that denying MAT to an incarcerated person with OUD violated the ADA and Eighth Amendment
- *In re: National Prescription Opiate Litigation*, MDL No. 2804 (N.D. Ohio) -- Multidistrict litigation consolidating thousands of opioid lawsuits
- *State of Oklahoma v. Johnson & Johnson*, No. CJ-2017-816 (Cleveland County, Okla. 2019) -- $465 million judgment against J&J (later reversed by Oklahoma Supreme Court on public nuisance grounds)

### Key Federal Statutes

- Controlled Substances Act, 21 U.S.C. 801 et seq.
- SUPPORT for Patients and Communities Act, Pub. L. No. 115-271 (2018)
- Comprehensive Addiction and Recovery Act, Pub. L. No. 114-198 (2016)
- 21st Century Cures Act, Pub. L. No. 114-255 (2016)
- Consolidated Appropriations Act, 2023, Pub. L. No. 117-328 (2022) (X-waiver elimination)

### Settlement Resources

- National Opioid Settlement information: https://nationalopioidsettlement.com/
- Johns Hopkins Bloomberg School: "Principles for the Use of Funds from the Opioid Litigation" (2020)
- KFF (Kaiser Family Foundation) opioid settlement fund tracker

---

## Documentaries and Media

- *Dopesick* (Hulu, 2021) -- Limited series adapted from Beth Macy's book, dramatizing Purdue Pharma's role
- *The Crime of the Century* (HBO, 2021) -- Alex Gibney documentary on pharmaceutical industry practices
- *Heroin(e)* (Netflix, 2017) -- Oscar-nominated short documentary on three women fighting the crisis in Huntington, WV
- *The Pharmacist* (Netflix, 2020) -- Documentary series about a pharmacist investigating opioid pill mills
- *All the Beauty and the Bloodshed* (2022) -- Documentary on artist Nan Goldin's campaign against the Sackler family

---

## Document Navigation

- Previous: [Roadmap](08-roadmap.md)
- Next: [Actions](10-actions.md)
- Up: [Overview](01-overview.md)
